Zobrazeno 1 - 10 of 11 pro vyhledávání: '"Daniel J Cloutier"'
1
Akademický článek
Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007)
Autor: Joseph L. Kuti, Aryun Kim, Daniel J. Cloutier, David P. Nicolau
Publikováno v: Infectious Diseases and Therapy, Vol 8, Iss 3, Pp 383-396 (2019)
Abstract Introduction CARE was a Phase 3, randomized study evaluating the efficacy and safety of plazomicin-based combination therapy compared with colistin-based combination therapy for the treatment of patients with bloodstream infections or hospit
Externí odkaz: https://doaj.org/article/b4ee00ea353e4bbc900e2cb69b8087c2
Zobrazit plný text záznamu
2
Akademický článek
Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections
Autor: Eliana S. Armstrong, Janelle A. Mikulca, Daniel J. Cloutier, Caleb A. Bliss, Judith N. Steenbergen
Publikováno v: BMC Infectious Diseases, Vol 16, Iss 1, Pp 1-6 (2016)
Abstract Background Fluoroquinolones are a guideline-recommended therapy for complicated urinary tract infections, including pyelonephritis. Elevated drug concentrations of fluoroquinolones in the urine and therapy with high-dose levofloxacin are bel
Externí odkaz: https://doaj.org/article/d8ad02f39611496d91cd976cefa11988
Zobrazit plný text záznamu
3
Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007)
Autor: Aryun Kim, Daniel J. Cloutier, David P. Nicolau, Joseph L. Kuti
Publikováno v: Infectious Diseases and Therapy
Infectious Diseases and Therapy, Vol 8, Iss 3, Pp 383-396 (2019)
Introduction CARE was a Phase 3, randomized study evaluating the efficacy and safety of plazomicin-based combination therapy compared with colistin-based combination therapy for the treatment of patients with bloodstream infections or hospital-acquir
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130b186933e9ec502e8772145f3a7c74
http://europepmc.org/articles/PMC6702525
Zobrazit plný text záznamu
4
Once-Daily Plazomicin for Complicated Urinary Tract Infections
Autor: Florian M E, Wagenlehner, Daniel J, Cloutier, Allison S, Komirenko, Deborah S, Cebrik, Kevin M, Krause, Tiffany R, Keepers, Lynn E, Connolly, Loren G, Miller, Ian, Friedland, Jamie P, Dwyer, Robert, Poirier
Publikováno v: The New England journal of medicine. 380(8)
The increasing multidrug resistance among gram-negative uropathogens necessitates new treatments for serious infections. Plazomicin is an aminoglycoside with bactericidal activity against multidrug-resistant (including carbapenem-resistant) Enterobac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9f420104a5ea4dd1ccf657b1feac3c6
https://pubmed.ncbi.nlm.nih.gov/31398750
Zobrazit plný text záznamu
5
124. Microbiological Outcomes With Plazomicin (PLZ) Versus Meropenem (MEM) in Patients With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in the EPIC Study
Autor: Kevin M. Krause, Allison Seiko Komirenko, Lynn E. Connolly, Tiffany R. Keepers, Daniel J Cloutier, Deborah S Cebrik
Publikováno v: Open Forum Infectious Diseases
Background PLZ is a next-generation aminoglycoside (AG) that is structurally protected from common AG-modifying enzymes (AMEs) in Enterobacteriaceae and with in vitro activity against multidrug-resistant Enterobacteriaceae, including ESBL-producing,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90bb3f59026e8b03a1d7a6c43920b111
http://europepmc.org/articles/PMC6253087
Zobrazit plný text záznamu
6
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials
Autor: David L. Paterson, Jennifer A. Huntington, Ellie Hershberger, Daniel J Cloutier, Benjamin F. Miller, Myra W. Popejoy, Caleb A. Bliss, Obiamiwe Umeh, Keith S. Kaye, Judith N. Steenbergen
Publikováno v: The Journal of antimicrobial chemotherapy. 72(1)
The increase in infections caused by drug-resistant ESBL-producing Enterobacteriaceae (ESBL-ENT) is a global concern. The characteristics and outcomes of patients infected with ESBL-ENT were examined in a pooled analysis of Phase 3 clinical trials of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c79c5861ce3530908d3fdf15955c918
https://pubmed.ncbi.nlm.nih.gov/27707990
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje